ABT Fair Value — Abbott Laboratories

Medical Devices · Institutional-depth multi-model valuation on Equity Rank

Current Price
$105.00
Consensus Fair Value
$103.02
Margin of Safety
-1.9%

When does ABT report earnings?

Abbott Laboratories (ABT) is next scheduled to report earnings on Oct 14, 2026. The consensus analyst EPS estimate for the upcoming quarter is $1.42.

Heading into this report, the model's fair value estimate sits 1.9% below the current price (model fair value differential below current price). Descriptive context only — not a forecast of the earnings result.

Earnings dates and estimates are sourced from third-party data and may change or lag. Informational only.

How ABT's valuation models agree

Equity Rank computed model fair value for ABT from 9 independent valuation methods with sufficient data. 4 place fair value above the current price of $105.00, and 5 place it below. The model-blended estimate lands at $103.02 — a model fair value differential of 1.9% below the current price under these model assumptions. The larger group places fair value below the current price.

Models: FV above price
4
Models: FV below price
5
Models compared
9

Each method (DCF, Graham Number, EPV, Three-Stage DCF, DDM, Residual Income, Justified Price-to-Book, and more) is weighted by historical sector accuracy. Model-derived and informational only — not investment advice.

ABT fundamental profile

Equity Rank's fundamental strength composite scores ABT at 69.7/100 (B, Solid), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at -1.8% per year and gross margin has moved +4.4 pp. Its SAVE composite score has moved -2.2 over the past 30 days.

A composite quality metric for research context — not a rating, recommendation, or directional signal.

About ABT

Abbott Laboratories (ABT) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.

Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.

Related Medical Devices Research

JNJ · UNH · PFE · ABBV · MRK

All Healthcare stocks with model fair values · Undervalued Healthcare stocks

Research Tools

Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator

Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks